ArticleJournal of artificial organs : the official journal of the Japanese Society for Artificial Organs2025
Outcomes of venovenous-extracorporeal membrane oxygenation bridging in lung transplant recipients with panel reactive antibody positivity.
Article in Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Post-transplant predictors of mortality and primary graft dysfunction in lung transplant recipients bridged with veno-venous extracorporeal membrane oxygenation.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026Article
- Impact of preoperative venovenous extracorporeal membrane oxygenation bridging on postoperative acute kidney injury after lung transplantation.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026Article
- Early safety observations of peri-transplant SGLT2 inhibitor use in lung transplant recipients.Journal of thoracic disease · 2026Article
- Observational
- Anticoagulation optimization and clinical impact of post-transplant deep vein thrombosis: clinical impact and a VV-ECMO subgroup analysis.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2026Article
- Glucagon-like peptide-1 receptor agonist use and clinical outcomes after lung transplantation: A single-center cohort study.JHLT open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung transplantation improves survival in advanced lung disease, but calculated Panel Reactive Antibody (cPRA) positive patients are at higher risk for adverse outcomes. It is unclear if sensitization poses additional risks in patients bridged to transplantation with venovenous extracorporeal membrane oxygenation (VV-ECMO). This study compares outcomes between cPRA-positive and -negative patients bridged with VV-ECMO.
methodsAmong 411 transplant recipients from an institutional lung transplantation database (January 2018-March 2025), 52 patients were bridged with VV-ECMO. Of these, 14 were cPRA-positive and 38 were cPRA-negative. Univariate and multivariate analyses evaluated early post-transplant complications and survival outcomes in cPRA-positive and -negative groups.
resultsRates of post-transplant complications such as primary graft dysfunction (PGD) in any grade (85.7% cPRA-positive vs. 76.4% cPRA-negative, p = 0.48), PGD grade 3 (35.7% vs. 50.0%, p = 0.53), acute kidney injury (AKI) (64.3% vs. 68.4%, p = 1.00), dialysis requirement (21.4% vs. 34.2%, p = 0.51), deep vein thrombosis (DVT) (71.4% vs. 55.3%, p = 0.35), and pulmonary embolism (PE) (7.1% vs. 18.4%, p = 0.42) were similar. 1-year survival rate (85.1% vs. 82.9%) and overall survival (p = 0.81) were not significantly different.
conclusionsPost-transplant outcomes and survival were similar between cPRA-positive and -negative groups, suggesting that PRA status in VV-ECMO bridged lung transplant recipients is not associated with worse outcomes. VV-ECMO may remain a viable bridge to lung transplantation, even in sensitized patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.